Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Nature Medicine explores the latest translational and clinical research news, with data from an ongoing clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma.
Nature Medicine explores the latest translational and clinical research news, with an immunotherapy that delays the onset of type 1 diabetes in high-risk children and adults.
Nature Medicine explores the latest translational and clinical research news, with news that sotatercept met its primary endpoint in the STELLAR trial.
Nature Medicine explores the latest translational and clinical research news, with an analysis of Intellia and Regeneron’s gene-editing treatment, which reduced levels of transthyretin in patients.
Millions have received the first dose of Sputnik V, but sanctions against its Russian developer may prevent the rollout of second doses, which could leave them under-vaccinated
As data emerge that boosters may help to protect against Omicron, the supply of vaccines to Africa is further squeezed. But fears of the COVID-19 variant may increase uptake, which is worryingly low in some countries.
Since the legalization of cannabis for recreational use in 2018, an expected boom in Canadian cannabis research has failed to happen, which has led scientists to demand changes in how clinical trials are regulated.
In the past year, there has been more CRISPR news than the awarding of the Nobel Prize in Chemistry to Jennifer Doudna and Emmanuelle Charpentier. Gene editing has continued its forward momentum in major ways, and scientists are beginning to see results.
Amid desperate efforts to find a treatment for the neurodegenerative disease Alzheimer’s, the aducanumab saga continues, as a US Food and Drug Administration panel will determine whether a post-hoc analysis of the arrested trials EMERGE and ENGAGE could be enough to approve the drug.
This week marks our last COVID-19 Research in Brief. COVID-19 research has been progressing at a staggering speed. But a lot still needs to be uncovered to effectively fight this pandemic. We look back at 6 months of biomedical research on COVID-19.